1Cree BA, Goodin DS, Hauser SL (2002) Neuromyelitisoptica. Semin Neurol 22: 105−122.
2Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica Devic's syndrome. Neurology 53: 1107−1114.
3Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10: 55−66.
4Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485−1489.
5Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, et al. (2008) Neuromyelitis optica and non-organ specific autoimmunity. Arch Neurol 65: 78–83.
6Fox RI (2005) Sjogren syndrome. The Lancet 366: 321 – 331.
7Wingerchuk DM, Weinshenker BG (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 18: 5–10.
8Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 326: 581–588.
9Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, et al. (2002) Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558.
10Bedi G, Usmani N, Delgado S, Sheremata W (2009) Prevalence and ethnic origin of patients with neuromyelitis optica in South Florida. Mult Scler 15: S34.
11Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodríguez R (2009) An epidemiological study of neuromyeliti s optica in Cuba. J Neurol 256: 35-44.
12Rivera JF, Kurtzke JF, Booth VJ, Corona V T 5th (2008) Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 255: 710-715.
13Cabre P, Heinzlef O, Merle H, Buisson GG, Bera O (2001) MS and neuromyelitis optica in Martinique (French West Indies). Neurology 56: 507-514.
14Wingerchuk DM, Weinshenker BG (2008) Neuromyelitis optica. Curr Treat Options Neurol 10: 55-66.
15Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106–2112.
16Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, et al. (2007) Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130: 1235−1243.
17Jarius S, Paul F, Franciotta D, Waters P, Zipp F, et al. (2008) Mechanism of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4: 202−214.
18Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, et al. (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17: 1019–1032.
19Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, et al. (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63: 964–968.
20Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman E, et al. (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73: 302-308.
21Gordon SK Yau, Jacky W Y Lee, Patrick PK Lau, Victor TY Tam, Winnie WY Wong, et al. (2013) Prospective Study on Retinal Nerve Fibre Layer Thickness Changes in Isolated Unilateral Retrobulbar Optic Neuritis. The Scientific World Journal.
22Weinshenker BG, Wingerchuk DM (2008) Neuromyelitis optica: Clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 318: 343–356.
23Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, et al. (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17: 1019–1032.
24Kolfenbach JR, Horner BJ, Ferucci ED, West SG (2011) Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res (Hoboken) 63: 1203–1208.
25Tan P, Yu WY, Umapathi T, Lim SA (2012) Severe optic neuritis in a patient with combined neuromyelitis optica spectrum disease and primary Sjögren's syndrome: a case report. Journal of Medical Case Reports 6: 401.